Last reviewed · How we verify
NCT03609008
The Effect of Levcromakalim Infusion on the Cranial Arteries Over Several Hours Using a High Resolution MRA Technique in a Randomized, Double-blind Placebo-controlled Design in Healthy Volunteers.
NA trial testing Levcromakalim in Dilatation of Cranial Arteries; MMA, STA and MCA in 20 participants. Completed in 15 August 2018.
15 August 2018
Quick facts
| Lead sponsor | Danish Headache Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | other |
| Enrollment | 20 |
| Start date | 26 June 2018 |
| Primary completion | 15 August 2018 |
| Estimated completion | 15 August 2018 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Levcromakalim — full drug profile →
- Saline
Conditions studied
- Dilatation of Cranial Arteries; MMA, STA and MCA — all drugs for Dilatation of Cranial Arteries; MMA, STA and MCA →
- Headache — all drugs for Headache →
Sponsor
Danish Headache Center — full company profile →
Who can join
Adults 18 to 60, any sex, with Dilatation of Cranial Arteries; MMA, STA and MCA or Headache. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Healthy participants vill randomly be allocated in a 2:1 order to receive 1 mg levcromakalim or placebo (isotonic saline) for 20 min. The investigator here examine the effect of levcromakalim infusion on the MMA and the MCA circumference over several hours using a high resolution MRA technique in a randomized, double-blind placebo-controlled design in healthy volunteers. The investigator hypothesized that levcromakalim induces dilatation of cranial arteries.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03609008
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Levcromakalim
Trials testing the same drug.
- NCT05889442 — Effect of Levcromakalim in Individuals With Migraine Pretreated With Erenumab · NA · completed
- NCT05565001 — The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. · NA · unknown
- NCT05243953 — Hypersensitivity to Opening of ATP-Sensitive Potassium Channels in Post-Traumatic Headache · NA · completed
- NCT05211050 — Effect of Sumatriptan on Levcromakalim-Induced Symptoms in Individuals With Migraine · NA · completed
- NCT04905654 — Migraine Inducing Effect of Levcromakalim in Patients With Migraine With Aura · NA · completed
Other Danish Headache Center trials
Trials by the same sponsor.
- NCT07451769 — Selective Activation of the Adrenomedullin Receptors in Migraine · NA · not yet recruiting
- NCT07342296 — Induction of Migraine Attacks With Aura Using Pituitary Adenylate Cyclase Activating Polypeptide-38 · NA · not yet recruiting
- NCT07059546 — Hypersensitivity to Adrenomedullin in Post-Traumatic Headache · NA · recruiting
- NCT07021859 — Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide · NA · recruiting
- NCT06959004 — Substance P-Induced Migraine Attacks Without Aura · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03609008 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Danish Headache Center
- Last refreshed: 5 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03609008.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing